Pluribus Labs’s Merck MRK Stock Holding History

Pluribus Labs’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1.41M	Buy	15,483 +9,078	+142%	+$805K	2.58%	6
2022 Q1	$526K	Buy	+6,405	New	+$505K	2.09%	11

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Pluribus Labs's MRK Position: Q2 2022 in Review

Pluribus Labs increased its Merck (MRK) stake by 142% in Q2 2022, buying an estimated $805K and bringing the position to 15,483 shares worth $1.41M. The position accounts for 2.58% of the portfolio, ranked #6.

Pluribus Labs first reported a position in MRK in Q1 2022 and has held it in 2 quarters since. 3,013 funds tracked by Wall St. Rank hold MRK as of Q2 2022.

Pluribus Labs held 15,483 shares of Merck worth $1.41M as of Q2 2022.
Pluribus Labs bought 9,078 Merck shares in Q2 2022, an estimated $805K.
Merck made up 2.58% of Pluribus Labs's portfolio in Q2 2022, its #6 holding.
Pluribus Labs first reported a position in Merck in Q1 2022 and has held it in 2 quarters since.
3,013 funds tracked by Wall St. Rank held Merck as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.